A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY 10019, USA. msherrid@chpnet.org
Mark V
MV
Sherrid
Milla
M
Arabadjian
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy* / Q000209:etiology; D004206:Disopyramide / Q000627:therapeutic use*; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D014694:Ventricular Outflow Obstruction / Q000150:complications / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D004206:Disopyramide